TickerStat.comEloxx Pharmaceuticals annual free cash flow per share
2010
2011
2012
2013
2014
2015
2015
2016
2016
2017
2017
2018
2019
2021
2022
Eloxx Pharmaceuticals Free Cash Flow Per Share Growth & History (ELOX)
Eloxx Pharmaceuticals's free cash flow per share was -$162.04 for fiscal 2022.
View full Eloxx Pharmaceuticals company overviewEloxx Pharmaceuticals annual free cash flow per share history
| Fiscal year | Period ended | Free cash flow per share | Change | Growth |
|---|---|---|---|---|
| 2022 | 2022-12-31 | -$162.04 | $58.65 | — |
| 2021 | 2021-12-31 | -$220.68 | — | — |
| 2019 | 2019-12-31 | -$455.81 | -$27.13 | — |
| 2018 | 2018-12-31 | -$428.68 | $1,001.21 | — |
| 2017 · Dec 31 | 2017-12-31 | -$1,429.89 | -$500.77 | — |
| 2017 · Jun 30 | 2017-06-30 | -$36.53 | $43.06 | — |
| 2016 · Dec 31 | 2016-12-31 | -$929.12 | -$319.77 | — |
| 2016 · Jun 30 | 2016-06-30 | -$79.59 | $148.31 | — |
| 2015 · Dec 31 | 2015-12-31 | -$609.34 | — | — |
| 2015 · Jun 30 | 2015-06-30 | -$227.90 | $163.46 | — |
| 2014 | 2014-06-30 | -$391.36 | $865.76 | — |
| 2013 | 2013-06-30 | -$1,257.13 | $996.96 | — |
| 2012 | 2012-06-30 | -$2,254.08 | $1,168.74 | — |
| 2011 | 2011-06-30 | -$3,422.82 | $3,747.41 | — |
| 2010 | 2010-06-30 | -$7,170.23 | — | — |
Eloxx Pharmaceuticals quarterly free cash flow per share
Q1.12
Q2.12
Q3.12
Q1.13
Q2.13
Q3.13
Q1.14
Q2.14
Q3.14
Q1.15
Q2.15
Q3.15
Q1.16
Q4.15
Q1.16
Q1.17
Q4.17
Q1.18
Q1.18
Q2.18
Q3.18
Q1.19
Q2.19
Q3.19
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
| Fiscal quarter | Period ended | Free cash flow per share | Change | YoY change |
|---|---|---|---|---|
| Q3 2023 | 2023-09-30 | -$13.81 | $21.70 | — |
| Q2 2023 | 2023-06-30 | -$10.27 | $39.26 | — |
| Q1 2023 | 2023-03-31 | -$34.60 | $13.65 | — |
| Q3 2022 | 2022-09-30 | -$35.51 | — | — |
| Q2 2022 | 2022-06-30 | -$49.53 | — | — |
| Q1 2022 | 2022-03-31 | -$48.25 | — | — |
| Q3 2019 | 2019-09-30 | -$124.98 | -$22.78 | — |
| Q2 2019 | 2019-06-30 | -$116.72 | $1.50 | — |
| Q1 2019 | 2019-03-31 | -$112.77 | -$20.80 | — |
| Q3 2018 | 2018-09-30 | -$102.20 | -$35.88 | — |
| Q2 2018 | 2018-06-30 | -$118.22 | $215.86 | — |
| Q1 2018 · Mar 31 | 2018-03-31 | -$91.97 | $201.52 | — |
| Q1 2018 · Sep 30 | 2017-09-30 | -$66.33 | — | — |
| Q4 2017 · Jun 30 | 2017-06-30 | -$334.09 | — | — |
| Q1 2017 · Mar 31 | 2017-03-31 | -$293.49 | -$275.37 | — |
| Q1 2016 · Mar 31 | 2016-03-31 | -$18.12 | $27.83 | — |
| Q4 2015 | 2015-12-31 | -$21.29 | $28.52 | — |
| Q1 2016 · Sep 30 | 2015-09-30 | -$24.90 | $39.09 | — |
| Q3 2015 | 2015-03-31 | -$45.95 | $72.07 | — |
| Q2 2015 | 2014-12-31 | -$49.81 | $131.90 | — |
| Q1 2015 | 2014-09-30 | -$63.99 | $63.83 | — |
| Q3 2014 | 2014-03-31 | -$118.02 | $415.67 | — |
| Q2 2014 | 2013-12-31 | -$181.71 | $30.97 | — |
| Q1 2014 | 2013-09-30 | -$127.82 | $133.33 | — |
| Q3 2013 | 2013-03-31 | -$533.70 | -$48.88 | — |
| Q2 2013 | 2012-12-31 | -$212.68 | $498.63 | — |
| Q1 2013 | 2012-09-30 | -$261.15 | $415.35 | — |
| Q3 2012 | 2012-03-31 | -$484.82 | — | — |
| Q2 2012 | 2011-12-31 | -$711.31 | — | — |
| Q1 2012 | 2011-09-30 | -$676.50 | — | — |
Eloxx Pharmaceuticals free cash flow per share trends
Over the last five fiscal years, Eloxx Pharmaceuticals's free cash flow per share increased from -$1,429.89 to -$162.04, a change of $1,267.86. The latest reported quarter, Q3 2023, shows -$13.81.
About the metric
What free cash flow per share means
Free cash flow per share estimates the free cash flow generated for each weighted-average common share. It combines operating cash generation, capital spending, and the share base into a per-share measure that can be compared over time.
Calculation and source
How free cash flow per share is calculated
TickerStat calculates free cash flow as operating cash flow minus capital expenditures, then divides it by basic weighted-average shares for the aligned fiscal period. Reliable filing-derived share counts are used when a filer omits the direct weighted-average-share fact. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Eloxx Pharmaceuticals source filings ↗Community posts
Eloxx doses first patients in mid-stage Alport syndrome trial
Eloxx Pharmaceuticals ($ELOX) dosed the first two patients in its Phase 2b EXACT study of exaluren for Alport syndrome caused by nonsense mutations. The trial plans to enroll 24 patients with relevant mutations in the COL4A3, COL4A4 or COL4 ...